[HTML][HTML] nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors
Journal of Clinical Oncology, 2021•ncbi.nlm.nih.gov
PURPOSE Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive
sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm,
registration trial is the first prospective clinical trial in this disease, investigating the safety
and efficacy of the mammalian target of rapamycin inhibitor nab-sirolimus (AMPECT,
sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm,
registration trial is the first prospective clinical trial in this disease, investigating the safety
and efficacy of the mammalian target of rapamycin inhibitor nab-sirolimus (AMPECT,
PURPOSE
Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investigating the safety and efficacy of the mammalian target of rapamycin inhibitor nab-sirolimus (AMPECT,
ncbi.nlm.nih.gov